Positive News SentimentPositive News Aurinia Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AUPH) $8.82 -0.24 (-2.65%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$8.68▼$9.1350-Day Range$7.13▼$9.2452-Week Range$4.07▼$12.43Volume2.40 million shsAverage Volume2.59 million shsMarket Capitalization$1.27 billionP/E RatioN/ADividend YieldN/APrice Target$14.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Aurinia Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside58.7% Upside$14.00 Price TargetShort InterestBearish11.97% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.51) to ($0.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.88 out of 5 starsMedical Sector716th out of 952 stocksPharmaceutical Preparations Industry336th out of 434 stocks 3.5 Analyst's Opinion Consensus RatingAurinia Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.00, Aurinia Pharmaceuticals has a forecasted upside of 58.7% from its current price of $8.82.Amount of Analyst CoverageAurinia Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted11.97% of the outstanding shares of Aurinia Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAurinia Pharmaceuticals has a short interest ratio ("days to cover") of 9.2.Change versus previous monthShort interest in Aurinia Pharmaceuticals has recently decreased by 0.52%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAurinia Pharmaceuticals does not currently pay a dividend.Dividend GrowthAurinia Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AUPH. Previous Next 3.2 News and Social Media Coverage News SentimentAurinia Pharmaceuticals has a news sentiment score of 1.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Aurinia Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 24 people have searched for AUPH on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat Follows5 people have added Aurinia Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aurinia Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.30% of the stock of Aurinia Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 39.64% of the stock of Aurinia Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aurinia Pharmaceuticals are expected to grow in the coming year, from ($0.51) to ($0.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aurinia Pharmaceuticals is -16.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aurinia Pharmaceuticals is -16.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAurinia Pharmaceuticals has a P/B Ratio of 3.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aurinia Pharmaceuticals Stock (NASDAQ:AUPH)Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.Read More AUPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AUPH Stock News HeadlinesDecember 2, 2023 | finance.yahoo.comInvestors in Aurinia Pharmaceuticals (NASDAQ:AUPH) have seen favorable returns of 78% over the past yearNovember 23, 2023 | finance.yahoo.comCan Aurinia (AUPH) Climb 46.13% to Reach the Level Wall Street Analysts Expect?December 4, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 22, 2023 | seekingalpha.comAurinia Pharma goes negative even amid takeover speculationNovember 21, 2023 | msn.comAurinia Pharma jumps amid takeover speculationNovember 13, 2023 | businesswire.comAurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS ® (Voclosporin) in JapanNovember 13, 2023 | msn.comAurinia partner files for Japan approval of lupus nephritis drugNovember 7, 2023 | finance.yahoo.comWall Street Analysts See a 59.35% Upside in Aurinia (AUPH): Can the Stock Really Move This High?December 4, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 7, 2023 | finance.yahoo.comAurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023November 3, 2023 | msn.comAre Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?November 3, 2023 | finance.yahoo.comAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2023 Earnings Call TranscriptNovember 3, 2023 | finance.yahoo.comAre Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?November 2, 2023 | finance.yahoo.comAurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus NephritisOctober 26, 2023 | finance.yahoo.comAurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus NephritisOctober 19, 2023 | finance.yahoo.comAurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023October 16, 2023 | finance.yahoo.comPfizer (PFE) Cuts 2023 Outlook as COVID Products' Demand FallsOctober 13, 2023 | finance.yahoo.comAurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR)October 9, 2023 | finance.yahoo.comJ&J (JNJ) Seeks EU Nod for Rybrevant for First-Line NSCLCOctober 3, 2023 | finance.yahoo.comLilly's (LLY) Eczema Candidate Lebrikizumab Faces FDA RejectionSeptember 27, 2023 | finance.yahoo.comIs it a Good Time to Invest in Aurinia Pharmaceuticals (AUPH)?September 27, 2023 | seekingalpha.comAurinia Rides High On Lupkynis, But Not Without Cost (Rating Upgrade)September 21, 2023 | finance.yahoo.comAurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT CapitalSeptember 18, 2023 | msn.comWhy Aurinia Pharmaceuticals Stock Is Slumping TodaySeptember 18, 2023 | finance.yahoo.com5 Stocks to Buy as Drug Industry Displays Strong FundamentalsSeptember 11, 2023 | finance.yahoo.comHere's Why We're Not At All Concerned With Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn SituationSeptember 6, 2023 | finance.yahoo.comWall Street Analysts Think Aurinia (AUPH) Could Surge 42.86%: Read This Before Placing a BetSee More Headlines Receive AUPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2023Today12/04/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AUPH CUSIPN/A CIK1600620 Webwww.auriniapharma.com Phone250-708-4272Fax250-744-2498Employees300Year FoundedN/APrice Target and Rating Average Stock Price Target$14.00 High Stock Price Target$15.00 Low Stock Price Target$13.00 Potential Upside/Downside+58.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-108,180,000.00 Net Margins-48.59% Pretax Margin-48.00% Return on Equity-19.54% Return on Assets-15.24% Debt Debt-to-Equity Ratio0.18 Current Ratio5.77 Quick Ratio5.33 Sales & Book Value Annual Sales$134.03 million Price / Sales9.45 Cash FlowN/A Price / Cash FlowN/A Book Value$2.85 per share Price / Book3.09Miscellaneous Outstanding Shares143,610,000Free Float137,433,000Market Cap$1.27 billion OptionableOptionable Beta1.25 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Peter S. Greenleaf M.B.A. (Age 53)President, CEO & Director Comp: $1.34MMr. Joseph M. Miller CPA (Age 49)Chief Financial Officer Comp: $791.92kMr. Matthew Maxwell Donley M.B.A. (Age 54)Executive Vice President of Operations & Strategy Comp: $811.82kMr. Stephen P. Robertson (Age 41)Executive VP, General Counsel, Corporate Secretary & Chief Compliance Officer Comp: $739.68kDr. Volker Knappertz D.Sc. (Age 58)M.D., Executive Vice President of Research & Development Comp: $742.85kMr. James Archie Harrell Jr. (Age 53)Head of Investor Relations Mr. Fran LynchVice President of SalesMr. Michael R. Martin (Age 51)Chief Business Officer Comp: $350.57kMs. Sue EvansSenior Vice President of Global Regulatory AffairsMr. Scott Habig (Age 63)Chief Commercial Officer More ExecutivesKey CompetitorsAgios PharmaceuticalsNASDAQ:AGIOCureVacNASDAQ:CVACPacira BioSciencesNASDAQ:PCRXMaravai LifeSciencesNASDAQ:MRVIOPKO HealthNASDAQ:OPKView All CompetitorsInsiders & InstitutionsGraham Capital Management L.P.Bought 68,448 shares on 11/22/2023Ownership: 0.048%Walleye Trading LLCBought 300 shares on 11/21/2023Ownership: 0.000%Ironwood Investment Management LLCSold 2,467 shares on 11/16/2023Ownership: 0.067%GTS Securities LLCBought 17,900 shares on 11/16/2023Ownership: 0.000%Tudor Investment Corp Et AlBought 13,533 shares on 11/16/2023Ownership: 0.009%View All Insider TransactionsView All Institutional Transactions AUPH Stock Analysis - Frequently Asked Questions Should I buy or sell Aurinia Pharmaceuticals stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AUPH shares. View AUPH analyst ratings or view top-rated stocks. What is Aurinia Pharmaceuticals' stock price target for 2024? 2 brokers have issued 12-month price targets for Aurinia Pharmaceuticals' stock. Their AUPH share price targets range from $13.00 to $15.00. On average, they expect the company's share price to reach $14.00 in the next year. This suggests a possible upside of 58.7% from the stock's current price. View analysts price targets for AUPH or view top-rated stocks among Wall Street analysts. How have AUPH shares performed in 2023? Aurinia Pharmaceuticals' stock was trading at $4.32 on January 1st, 2023. Since then, AUPH stock has increased by 104.2% and is now trading at $8.82. View the best growth stocks for 2023 here. When is Aurinia Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our AUPH earnings forecast. How were Aurinia Pharmaceuticals' earnings last quarter? Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) issued its quarterly earnings results on Thursday, November, 2nd. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.08. The biotechnology company earned $54.52 million during the quarter, compared to the consensus estimate of $38.41 million. Aurinia Pharmaceuticals had a negative trailing twelve-month return on equity of 19.54% and a negative net margin of 48.59%. What ETFs hold Aurinia Pharmaceuticals' stock? ETFs with the largest weight of Aurinia Pharmaceuticals (NASDAQ:AUPH) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP).ALPS Medical Breakthroughs ETF (SBIO). What other stocks do shareholders of Aurinia Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Exelixis (EXEL), AbbVie (ABBV), Amarin (AMRN) and Array Technologies (ARRY). Who are Aurinia Pharmaceuticals' major shareholders? Aurinia Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Armistice Capital LLC (4.21%), Northern Trust Corp (0.73%), Group One Trading L.P. (0.00%), Bank of New York Mellon Corp (0.28%), Charles Schwab Investment Management Inc. (0.27%) and Stifel Financial Corp (0.25%). Insiders that own company stock include David RW Jayne, George M Milne Jr, Jill Leversage, Joseph M Miller, Joseph P Hagan, Matthew Maxwell Donley, Michael Robert Martin, Neil Solomons, Peter Greenleaf, Robert Bindert Huizinga and Stephen P Robertson. View institutional ownership trends. How do I buy shares of Aurinia Pharmaceuticals? Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:AUPH) was last updated on 12/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.